Fig 1: miR-146a blocks the PI3K signaling pathway by inhibiting LAMC2. (A) Possible miR-146 binding sites in the LAMC2 3' untranslated region. (B) Impact of miR-146a on the luciferase activity of LAMC2-WT and LAMC2-MT evaluated by dual luciferase assays. *P<0.05 vs. LAMC2 MT. (C) LAMC2 expression in The Cancer Genome Atlas-ovarian cancer dataset (n=426 for tumor samples and n=88 for normal tissues) predicted by gene expression profiling interactive analysis. *P<0.05. (D) LAMC2 expression in SKOV3 and A2780 cells determined by RT-qPCR. *P<0.05 vs. cells treated with PBS; #P<0.05 vs. cells co-cultured with exosomes extracted from InC-treated MSCs. (E) Protein expression levels of PI3K measured by ELISA. *P<0.05 vs. cells treated with PBS; #P<0.05 vs. cells co-cultured with exosomes extracted from InC-treated MSCs. (F) LAMC2 expression in SKOV3/DTX and A2780/TAX cells determined by RT-qPCR. Data are presented as the mean ± SD. *P<0.05 vs. cells transfected with EV. One-way (panels D, E and F) or two-way (panel B) ANOVA and Tukey's multiple comparisons test were used to determine statistical significance. Each assessment was performed in triplicate with three repetitions to ensure minimum deviation. DTX, docetaxel; InC, inhibitor control; inhi, inhibitor; LAMC2, laminin ?2; miR, microRNA; MSCs, mesenchymal stem cells; MT, mutant; RT-qPCR, reverse transcription-quantitative PCR; TAX, taxane; WT, wild type.